US2012183533A1PendingUtilityA1

Mimotopes of hiv env

46
Individually held — no corporate assignee on recordPriority: Oct 30, 2008Filed: Mar 30, 2011Published: Jul 19, 2012
Est. expiryOct 30, 2028(~2.3 yrs left)· nominal 20-yr term from priority
Inventors:Ruth M. RuprechtMichael Paul Humbert
C07K 2317/24C07K 16/4216C07K 2317/76A61K 2039/55566A61K 39/12C12N 2740/16122A61K 2039/5256C12N 2795/00043C12N 2740/15022C07K 2319/00C12N 2740/16134A61P 31/18A61K 38/00A61K 39/21C07K 2317/34C07K 2318/10C07K 2317/55A61P 37/04C12N 7/00C07K 14/005A61K 2039/575C12N 2740/16171A61K 2039/53C07K 2317/21C07K 16/1145A61K 39/00
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS).

Claims

exact text as granted — not AI-modified
1 . An isolated HIV envelope-like polypeptide, wherein said polypeptide comprises an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of those recited in  FIG. 1  or  FIG. 9 . 
     
     
         2 . The isolated HIV envelope-like polypeptide of  claim 1 , wherein said polypeptide is a mimotope having an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-84. 
     
     
         3 . The isolated HIV envelope-like polypeptide of  claim 1 , wherein said polypeptide is a mimotope of an HIV V3 envelope region and comprises an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 21, 23, 25, 28, 29 and 31. 
     
     
         4 . The isolated HIV envelope-like polypeptide of  claim 1 , wherein said polypeptide is a mimotope of an HIV C-terminal envelope region and comprises an amino acid sequence which is 90% or more identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 37, 38 and 39. 
     
     
         5 . The isolated HIV envelope-like polypeptide of  claim 1 , wherein said polypeptide is a wild-type HIV envelope polypeptide consisting essentially of an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 85-92. 
     
     
         6 . The isolated HIV envelope-like polypeptide of  claim 3 , wherein said mimotope comprises an amino acid sequence which is 90% or more identical to the amino acid sequence of SEQ ID NO:31. 
     
     
         7 . The isolated HIV envelope-like polypeptide of  claim 3 , wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:31. 
     
     
         8 . The isolated HIV envelope-like polypeptide of any one of  claims 1 - 7 , wherein said polypeptide is a fusion polypeptide. 
     
     
         9 . A composition comprising the HIV envelope-like polypeptide of any one of  claims 1 - 8  and a pharmacologically acceptable carrier. 
     
     
         10 . A kit comprising the composition of  claim 9  and instructions for use. 
     
     
         11 . An isolated nucleic acid encoding one or more of the HIV envelope-like polypeptides of any one of  claims 1 - 8 . 
     
     
         12 . A vector comprising the nucleic acid molecule of  claim 11 . 
     
     
         13 . A host cell comprising the vector of  claim 12 . 
     
     
         14 . A composition comprising one or more of the isolated nucleic acids of  claim 11  and a pharmacologically acceptable carrier. 
     
     
         15 . A kit comprising the composition of  claim 14 , and instructions for use. 
     
     
         16 . A neutralizing antibody that specifically binds to an HIV C-terminal region of gp120. 
     
     
         17 . An antibody that specifically binds to an HIV envelope-like polypeptide, wherein said polypeptide comprises an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of those recited in  FIG. 1 . 
     
     
         18 . The antibody of  claim 17 , wherein said polypeptide is a mimotope comprising an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-84 or the amino acid sequences presented in  FIG. 9 . 
     
     
         19 . The antibody of  claim 17 , wherein said polypeptide is a wild-type HIV envelope polypeptide comprising an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 85-92. 
     
     
         20 . The antibody of  claim 17 , wherein said polypeptide is a mimotope of an HIV V3 region comprising an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 23, 25, 28, 29 and 31. 
     
     
         21 . The antibody of  claim 17 , wherein said polypeptide is a mimotope of an HIV C-terminal envelope polypeptide comprising an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 35, 37, 38 and 39. 
     
     
         22 . The antibody of  claim 20 , wherein said mimotope comprises an amino acid sequence which is 90% or more identical to the amino acid sequences of SEQ ID NO:31. 
     
     
         23 . The antibody of  claim 20 , wherein said mimotope comprises the amino acid sequence of SEQ ID NO:31. 
     
     
         24 . The antibody of any one of  claims 17 - 23 , wherein the antibody is an HIV neutralizing antibody. 
     
     
         25 . The antibody of any one of  claims 17 - 24 , wherein said antibody is a mouse or monkey antibody. 
     
     
         26 . The antibody of any one of  claims 17 - 24 , wherein said antibody is a human antibody. 
     
     
         27 . The antibody of any one of  claims 17 - 26 , wherein said antibody is a polyclonal antibody. 
     
     
         28 . The antibody of any one of  claims 17 - 26 , wherein said antibody is a monoclonal antibody. 
     
     
         29 . The antibody of any one of  claims 17 - 24 , wherein said antibody is a chimeric antibody. 
     
     
         30 . The antibody of any one of  claims 17 - 24 , wherein said antibody is a humanized antibody. 
     
     
         31 . The antibody of any one of  claims 17 - 30  wherein said antibody is a binding fragment. 
     
     
         32 . A composition comprising the antibody of any one of  claims 17 - 31  and a pharmacologically acceptable carrier. 
     
     
         33 . The antibody of any one of  claims 17 - 31  wherein said antibody is a Fab fragment. 
     
     
         34 . A kit comprising the composition of  claim 32  and instructions for use. 
     
     
         35 . A cell line expressing the antibody of any one of  claims 17 - 33 . 
     
     
         36 . A method for inducing an immune response in a subject comprising administering a pharmaceutical composition comprising an immunologically effective dose of an HIV envelope-like polypeptide, wherein said polypeptide comprises an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of those listed in  FIG. 1  or  FIG. 9 . 
     
     
         37 . The method of  claim 36 , wherein the polypeptide is a mimotope comprising an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-84. 
     
     
         38 . The method of  claim 36 , wherein the polypeptide is a wild-type HIV envelope polypeptide consisting essentially of an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 85-92. 
     
     
         39 . The method of  claim 36 , wherein the polypeptide is an HIV V3 region mimotope comprising an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 23, 25, 28, 29 and 31. 
     
     
         40 . The method of  claim 36 , wherein the polypeptide is an HIV C-terminal envelope mimotope comprising an amino acid sequence which is 90% or more identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 34, 35, 37, 38 and 39. 
     
     
         41 . The method of  claim 39 , wherein the mimotope comprises an amino acid sequence which is 90% or more identical to the amino acid sequence of SEQ ID NO:31. 
     
     
         42 . The method of  claim 39 , wherein the mimotope comprises the amino acid sequence of SEQ ID NO:31. 
     
     
         43 . The method of any one of  claims 36 - 43 , further comprising administering a nucleic acid encoding an HIV envelope polypeptide. 
     
     
         44 . A method for treating or preventing an HIV infection in a subject, the method comprising administering a therapeutically effective dose of an antibody that specifically binds to an HIV envelope-like polypeptide comprising an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of those recited in  FIG. 1  or  FIG. 9 . 
     
     
         45 . The method of  claim 44 , wherein the polypeptide is a mimotope comprising an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-84. 
     
     
         46 . The method of  claim 44 , wherein the polypeptide is an HIV V3 region mimotope having an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 23, 25 28, 29 and 31. 
     
     
         47 . The method of  claim 44 , wherein the polypeptide is an HIV C-terminal envelope mimotope comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 35, 37, 38 and 39. 
     
     
         48 . The method of  claim 44 , wherein the polypeptide is a wild type HIV envelope polypeptide comprising an amino acid sequence which is 90% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 85-92. 
     
     
         49 . The method of  claim 46 , wherein the mimotope comprises an amino acid sequence which is 90% or more identical to the amino acid sequences of SEQ ID NO:31. 
     
     
         50 . The method of  claim 46 , wherein the mimotope comprises the amino acid sequence of SEQ ID NO:31. 
     
     
         51 . The method of any one of  claims 36 - 50 , wherein the HIV envelope-like polypeptide is coupled to a immunocarrier. 
     
     
         52 . An antibody produced by a hybridoma selected from the group consisting of ATCC#s: 
     
     
         53 . A cell line deposited as ATCC#.

Join the waitlist — get patent alerts

Track US2012183533A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.